Calcium Channel Agonists and Antagonists: Effects of Chronic Treatment on Pituitary Prolactin Synthesis and Intracellular Calcium
- 31 October 1988
- journal article
- research article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 2 (11) , 1132-1138
- https://doi.org/10.1210/mend-2-11-1132
Abstract
PRL synthesis by GH cells in culture has previously been shown to increase when calcium is added to cultures grown in calcium-depleted medium or when cultures are treated for 18 h or longer with the dihydropyridine calcium channel agonist BAY K8644, whereas the antagonist nimodipine inhibits PRL. The experiments described here were designed to test whether differences in PRL synthesis caused by the dihydropyridines are due to changes in PRL mRNA levels, whether structurally different classes of calcium channel blockers alter PRL production, and whether long term treatment with calcium channel agonists and antagonists alters intracellular free calcium, [Ca2+]i. PRL synthesis and PRL mRNA levels were increased similarly by BAY K8644 and decreased in parallel by the dihydropyridine antagonist nimodipine, while overall protein and RNA synthesis were not changed by either the agonist or antogonist. Two calcium channel blockers which act at different sites on L-type channels than the dihydropyridines also inhibited PRL synthesis without affecting GH; 5 .mu.M verapamil reduced PRL by 64% and 15 .mu.M diltiazem by 89%. Partial depolarization with 5-25 mM KCl increased PRL synthesis up to 2-fold. The intracellular free calcium ion concentration was estimated by Quin 2 and averaged 142 nM for control cultures in normal medium, and 128 and 168 nM for cultures treated 72 h with nimodipine or BAY K8644, respectively. Nimodipine totally prevented the calcium rise obtained upon depolarization. The resting intracellular calcium concentration and PRL synthesis were lower for cultures grown in serum-free medium with no added calcium (85 nM [Ca2+]i, 1.88 .mu.g PRL) than for those grown in serum-free medium with added calcium and BAY K8644 (400 nM [Ca2+]i, 6.75 .mu.g PRL). These data support the conclusion that drugs like the dihydropyridines, verapamil, and deltiazem regulate PRL synthesis selectively via an effect on PRL mRNA levels and that this results from actions at L-type voltage sensitive calcium channels.Keywords
This publication has 15 references indexed in Scilit:
- Molecular mechanisms of phorbol ester, thyrotropin-releasing hormone, and growth factor stimulation of prolactin gene transcription.Journal of Biological Chemistry, 1985
- Dihydropyridine Ca2+ antagonists: potent inhibitors of secretion from normal and transformed pituitary cellsAmerican Journal of Physiology-Cell Physiology, 1985
- Differential Effects of Thyrotropin-Releasing Hormone,Vasoactive Intestinal Peptide, Phorbol Ester, and Depolarization in GH4C1Rat Pituitary Cells*Endocrinology, 1985
- Epidermal growth factor and thyrotropin-releasing hormone interact synergistically with calcium to regulate prolactin mRNA levels.Journal of Biological Chemistry, 1983
- Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cellsNature, 1983
- Calcium specifically stimulates prolactin synthesis and messenger RNA sequences in GH3 cells.Journal of Biological Chemistry, 1981
- Electrical behaviour in a line of anterior pituitary cells (GH cells) and the influence of the hypothalamic peptide, thyrotrophin releasing factorNeuroscience, 1980
- Membrane potential changes caused by thyrotropin-releasing hormone in the clonal GH3 cell and their relationship to secretion of pituitary hormone.Proceedings of the National Academy of Sciences, 1979
- Establishment of Clonal Strains of Rat Pituitary Tumor Cells That Secrete Growth Hormone1,2Endocrinology, 1968
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951